FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?

Gallo, Leandro H.

doi:10.18632/oncotarget.27957

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FGFR1 amplification is associated with upregulation of fibroblast growth factor receptor 1, which is responsible for the activation of multiple downstream oncogenic pathways, such as those associated with MAPK, AKT, and STAT signaling (12). Overexpression of fibroblast growth factor receptor 1 correlates with resistance to letrozole and cyclin-dependent kinase inhibitors in breast cancer (13,14).…”

Section: Discussionmentioning

confidence: 99%

Prediction of Resistance to¹⁷⁷Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers

Sartor,

Ledet,

Huang

et al. 2023

J Nucl Med

View full text Add to dashboard Cite

Lu-PSMA-617 and 177 Lu-PSMA I&T (collectively termed 177 Lu-PSMA) are currently being used for the treatment of selected metastatic castration-resistant prostate cancer (mCRPC) patients with PSMA PET-positive disease, but biomarkers for these agents remain incompletely understood. Methods: Pretreatment circulating tumor DNA (ctDNA) samples were collected from 44 mCRPC patients receiving 177 Lu-PSMA treatment. Prostate-specific antigen responders and nonresponders were assessed relative to the ctDNA findings at baseline. Results: The ctDNA findings indicated that nonresponders were more likely to have gene amplifications than were responders (75% vs. 39.2%, P 5 0.03). In particular, amplifications in FGFR1 (25% vs. 0%, P 5 0.01) and CCNE1 (31.2% vs. 0%, P 5 0.001) were more likely to be present in nonresponders. CDK12 mutations were more likely to be present in nonresponders (25% vs. 3.6%, P 5 0.05). Conclusion: Our analyses indicate that ctDNA assays may contain specific biomarkers predictive of response or resistance for 177 Lu-PSMA-treated mCRPC patients. Additional confirmatory studies are required before clinicians can use these findings to make personalized treatment decisions.

show abstract

Section: Discussionmentioning

confidence: 99%

Prediction of Resistance to¹⁷⁷Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers

Sartor,

Ledet,

Huang

et al. 2023

J Nucl Med

View full text Add to dashboard Cite

show abstract

Fibroblast growth factor 2: Role in prenatal alcohol-induced stimulation of hypothalamic peptide neurons

Chang¹,

Yasmin²,

Collier³

et al. 2022

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?

Cited by 2 publications

References 10 publications

Prediction of Resistance to¹⁷⁷Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers

Prediction of Resistance to¹⁷⁷Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers

Fibroblast growth factor 2: Role in prenatal alcohol-induced stimulation of hypothalamic peptide neurons

Contact Info

Product

Resources

About

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?

Cited by 2 publications

References 10 publications

Prediction of Resistance to177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers

Prediction of Resistance to177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers

Fibroblast growth factor 2: Role in prenatal alcohol-induced stimulation of hypothalamic peptide neurons

Contact Info

Product

Resources

About

Prediction of Resistance to¹⁷⁷Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers

Prediction of Resistance to¹⁷⁷Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers